# US 2014/0193512 A1 · Clotting cascade initiating apparatus and methods of use and methods of closing wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193512 A1
- Document ID: US20140193512A1
- Status: Published application
- Kind: A1
- Application number: 14/146,139
- Filed: 2014-01-02
- Published: 2014-07-10
- Earliest claimed: 1997-12-16
- Assignees: Closys Corporation
- Applicants: Closys Corporation
- Inventors: Karol L. Nowakowski
- Web page: https://patentgrep.com/patent/US20140193512A1

## CPC

- A61L 24/0005: {Ingredients of undetermined constitution or reaction products thereof}
- A61B 17/00491: {Surgical glue applicators}
- A61B 17/0057: {Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect (sutures A61B17/04; closing rectum or urethra near body surface A61F2/0009)}
- A61B 2017/00637: {for sealing trocar wounds through abdominal wall}
- A61B 2017/00641: {for closing fistulae, e.g. anorectal fistulae}
- A61B 2017/0065: {the implement being an adhesive}
- A61M 25/0662: {Guide tubes}
- A61M 2025/0681: {Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing coagulated blood to the wound site to complete clotting. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

## Claims

### Claim 1

A method of closing a wound in a patient, the method comprising the steps of:
a) treating a blood fluid such that at least a portion of the blood fluid will form a clot of blood subsequent to the treatment, the blood fluid containing sufficient blood components to enable a portion of the blood fluid to clot subsequent to the treatment once a clotting cascade is initiated, the blood components being selected from the group consisting of whole blood, natural components of whole blood, whether derived from whole blood, blood extracts, or products of ex-vivo cell cultures, and procoagulating agents which assist in or enhance the clotting or coagulation of the blood fluid, the step of treating the blood fluid including initiating the clotting cascade; and
b) transporting the treated blood fluid to the wound in the patient such that the blood fluid can come into contact with the patient proximate the wound and the clotting cascade can come generally to a conclusion and a clot can form proximate the wound such that a clot is formed in the wound which prevents fluid from passing through the wound.

### Claim 2 (depends on 1)

The method of claim 1, the step of treating the blood fluid including (1) providing a containment chamber in which the blood fluid can be contained, (2) placing the blood fluid in the containment chamber; and (3) initiating the clotting cascade by exposing the blood fluid to a procoagulating agent within the containment chamber.

### Claim 3 (depends on 2)

The method of claim 2, the step of treating the blood fluid including providing a substantially enclosed sterile containment chamber, the chamber containing a procoagulating agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the procoagulating agent is a porous matrix and the step of treating the blood fluid includes passing the blood fluid through the porous matrix.

### Claim 5 (depends on 4)

The method of claim 4, wherein the porous matrix is biological in origin and comprises a biologic material, and the step of treating the blood fluid includes exposing the blood fluid to the biologic material such that the clotting cascade is initiated within the blood fluid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the biologic material is selected from the group consisting of cotton and diatomaceous earth.

### Claim 7 (depends on 4)

The method of claim 4, wherein the porous matrix is an inorganic material and the step of treating the blood fluid includes exposing the blood fluid to the inorganic material such that the clotting cascade is initiated within the blood fluid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the inorganic material is glass.

### Claim 9 (depends on 4)

The method of claim 4, wherein the porous matrix is a synthetic polymer and the step of treating the blood fluid includes exposing the blood fluid to the synthetic polymer such that the clotting cascade is initiated within the blood fluid.

### Claim 10 (depends on 9)

The method of claim 9, wherein the synthetic polymer is a selected from the group consisting of dacron, silicone, polyurethane, polycarbonate, polyethylene, and polyvinylchloride.

### Claim 11

A clotting cascade initiation apparatus within which a blood fluid can be received, the blood fluid being useful for treatment of a wound within a patient, said apparatus comprising:
a substantially enclosed sterile containment chamber within which the blood fluid can be received and retained; and
a procoagulating agent within the substantially enclosed sterile containment chamber, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber and exposed to the procoagulating agent, and the blood fluid can be delivered to the wound within the patient subsequent to the initiation of the clotting cascade such that the clotting cascade can be completed within the wound and a clot can form within the wound.

### Claim 12 (depends on 11)

The clotting cascade initiation apparatus of claim 11, further including a cannula for delivering blood fluid to the wound, the cannula being in communication with the containment chamber.

### Claim 13 (depends on 11)

The clotting cascade initiation apparatus of claim 11, further including a cannula for withdrawing blood fluid from the patient and delivering blood fluid to the wound, the cannula being in communication with the containment chamber.

### Claim 14 (depends on 11)

The clotting cascade initiation apparatus of claim 11, wherein the procoagulating agent is a porous matrix through which the blood fluid can be passed.

### Claim 15 (depends on 14)

The clotting cascade initiation apparatus of claim 14, wherein the porous matrix is biological in origin and comprises a biologic material.

### Claim 16 (depends on 15)

The clotting cascade initiation apparatus of claim 15, wherein the biologic material is selected from the group consisting of cotton and diatomaceous earth.

### Claim 17 (depends on 14)

The clotting cascade initiation apparatus of claim 14, wherein the porous matrix is an inorganic material.

### Claim 18 (depends on 17)

The clotting cascade initiation apparatus of claim 17, wherein the inorganic material is glass.

### Claim 19 (depends on 14)

The clotting cascade initiation apparatus of claim 14, wherein the porous matrix is a synthetic polymer.

### Claim 20 (depends on 19)

The clotting cascade initiation apparatus of claim 19, wherein the synthetic polymer is a synthetic polymer selected from the group consisting of dacron, silicone, polyurethane, polycarbonate, polyethylene, and polyvinylchloride.

### Claim at position 21

21-47. (canceled)